Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad Income Statement

Financials in millions MYR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	883.47	813.7	704.73	696.72	639.18	569.9
Revenue Growth (YoY)	26.71%	15.46%	1.15%	9.00%	12.16%	-1.14%
Cost of Revenue	562.91	512.16	436.4	416.9	385.19	336.7
Gross Profit	320.56	301.54	268.33	279.82	253.98	233.2
Selling, General & Admin	208.43	202.02	182.72	186.59	165.78	150.81
Other Operating Expenses	0.15	0.7	2.8	0.81	-0.67	1.35
Operating Expenses	207.15	201.28	189.61	186.91	165.22	151.35
Operating Income	113.41	100.26	78.71	92.91	88.77	81.86
Interest Expense	-25.06	-25.77	-17.68	-9.1	-6.44	-6.53
Interest & Investment Income	5.74	5.97	2.75	1.52	1.2	1.51
Other Non Operating Income (Expenses)	-0.82	-0.82	-0.52	-0.48	-0.53	-0.68
EBT Excluding Unusual Items	93.27	79.63	63.27	84.85	82.99	76.16
Gain (Loss) on Sale of Assets	0.39	0.39	-	-	-0.01	-
Pretax Income	93.66	80.02	63.27	84.85	82.98	76.16
Income Tax Expense	20.65	17.38	10.62	14.74	17.3	17.55
Net Income	73.01	62.65	52.65	70.11	65.68	58.61
Net Income to Common	73.01	62.65	52.65	70.11	65.68	58.61
Net Income Growth	61.20%	19.00%	-24.91%	6.74%	12.07%	6.04%
Shares Outstanding (Basic)	962	962	959	948	928	928
Shares Outstanding (Diluted)	962	962	959	948	928	928
Shares Change (YoY)	0.13%	0.36%	1.08%	2.15%	0.02%	3.86%
EPS (Basic)	0.08	0.07	0.05	0.07	0.07	0.06
EPS (Diluted)	0.08	0.07	0.05	0.07	0.07	0.06
EPS Growth	61.00%	18.57%	-25.71%	4.50%	12.05%	2.09%
Free Cash Flow	87.5	59.77	15.86	5.08	-66.16	15.24
Free Cash Flow Per Share	0.09	0.06	0.02	0.01	-0.07	0.02
Dividend Per Share	0.030	0.030	0.023	0.023	0.022	0.049
Dividend Growth	30.44%	30.44%	-	5.75%	-55.43%	8.44%
Gross Margin	36.28%	37.06%	38.07%	40.16%	39.74%	40.92%
Operating Margin	12.84%	12.32%	11.17%	13.33%	13.89%	14.36%
Profit Margin	8.26%	7.70%	7.47%	10.06%	10.28%	10.28%
Free Cash Flow Margin	9.90%	7.35%	2.25%	0.73%	-10.35%	2.67%
EBITDA	150.41	137.34	114.04	122.86	114.94	105.93
EBITDA Margin	17.02%	16.88%	16.18%	17.63%	17.98%	18.59%
D&A For EBITDA	37	37.08	35.32	29.95	26.18	24.08
EBIT	113.41	100.26	78.71	92.91	88.77	81.86
EBIT Margin	12.84%	12.32%	11.17%	13.33%	13.89%	14.36%
Effective Tax Rate	22.05%	21.72%	16.79%	17.37%	20.85%	23.04%

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.